Pharma Business - February 28, 2018
MedImmune to create stand-alone company
AstraZeneca’s global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease. MedImmune will contribute three clinical and three pre-clinical […]